艾昆纬-释放生物仿制药潜力（英）-2026.2.pdfVIP

Unlocking

BiosimilarPotential

OphthalmologyCaseStudy

FEBRUARY

2026

Introduction

Ensuringthatchallengestobiosimilaruptakearecontinuouslyassessedand

addressedisacriticalpartofunlockingtheirbenefits.Biosimilaruseisgrowing

acrosstherapyareaswithdifferentspecialtiesgainingexperienceandconfidence.

Thesebiosimilarshavealsoprovidedsubstantialsavingsfortheoverallhealth

system.Between2023and2025,IQVIAInstitutehaspublishedtworeports

highlightingtheimportanceofphysicianperspectivesonbiosimilarsfortheir

optimaluse,especiallyintherapyareaswhereoverallexperiencewithbiosimilars

hasbeenlimited.Whilecertainchallengestotheuptakeofbiosimilarsare

commonacrosstherapyareas,eachnewareaprovidessomeuniquedynamics.

Assessmentofthesedynamicscanallowstakeholderstoworktogetherand

ensurethatoptimalbenefitsareachieved.

ThisreportpresentsacasestudyofOphthalmologyThereportutilizestheinterviewstohighlightsome

whichsawtherecententryofafliberceptbiosimilarspossiblesolutionstoovercomechallengesregarding

in2025.Ophthalmologyhadalsoseentheentryofthevariablelevelofknowledgeandexperiencewith

ranibizumabbiosimilarsin2022,however,theuptakeofbiosimilarsalongwithotherstructuralchallenges.

thebiosimilarwaslimited.Withafliberceptbiosimilars

enteringthistherapeuticareawiththepotentialtoThestudywasproducedindependentlybytheIQVIA

reducecostssubstantially,thereisaneedtoassessInstituteforHumanDataScience.Fundingforthis

challengesthattheymightface.ThedegreeoffamiliarityresearchandreporthasbeenprovidedbySandoz.

andpriorexperiencewithbiosimilars